ArticleMolecular and cellular biochemistry2026
LncRNA GATA3-AS1 affects the proliferation and apoptosis of cardiomyocytes through modulating miR-149-3p/NR2F2 axis.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Congenital heart disease (CHD) represents the most prevalent and life-threatening birth defect. The identification of underlying factors contributing to abnormal cardiac development can offer valuable insights for the comprehensive medical management of affected pediatric patients. This study aimed to investigate the role and underlying mechanisms of GATA3-AS1 in the progression of CHD. The proliferation ability and apoptosis level of AC16 cardiomyocytes overexpressing GATA3-AS1 were detected by CCK-8 assay and flow cytometry. The downstream target miRNAs and mRNAs of GATA3-AS1 were validated using qPCR and western blot to elucidate the GATA3-AS1-associated ceRNA regulatory network. The interaction between GATA3-AS1 and its downstream target genes was validated using the dual-luciferase reporter assay. Finally, the expression patterns of GATA3‑AS1 and its downstream target genes were validated in clinical samples. Cellular functional assays demonstrated that the overexpression of GATA3-AS1 significantly suppressed the proliferation of AC16 cardiomyocytes while inducing apoptosis in these cells. The qPCR analysis revealed that, in AC16 cells overexpressing GATA3-AS1, the expression levels of NR2F2 were significantly upregulated, whereas the expression levels of miR-149-3p and miR-6769b-5p were significantly downregulated. Additionally, Western blot analysis further validated the significant upregulation of NR2F2 protein expression. The dual-luciferase reporter gene assay confirmed that GATA3-AS1 regulated cellular biological behavior by competitively binding to miR-149-3p with NR2F2. Finally, qPCR confirmed that the expression of GATA3-AS1, miR-149-3p, and NR2F2 in clinical samples were consistent with cytological experiments. GATA3-AS1 regulates the proliferation and apoptosis of AC16 cells via the GATA3-AS1/has-miR-149-3p/NR2F2 axis, potentially contributing to the formulation of more personalized and effective medical management strategies for patients with CHD.
Indexed as
Identifiers
42418116What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.